Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen

키워드

참고문헌 (14)

1. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
2. Chevaliez S, "Long-term hepatitis B surface antigen(HBsAg)kinetics during nucleoside", nucleotide analogue therapy : finite treatment duration unlikely, 2013, pp.58, 676~683
3. Hsu YC, "Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B : First, do no harm", Clin Mol Hepatol, 29, pp.869~890 (2023)
4. Su TH, "Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy", J Infect Dis, 217, pp.1193~1201 (2018)
5. Hirode G, "Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B : An international, multicenter, multiethnic cohort(RETRACT-B study)", Gastroenterology, 162, pp.757~771 (2022)
6. Sonneveld MJ, "Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels", J Hepatol, 76, pp.1042~1050 (2022)
7. Testoni B, "Serum hepatitis B core-related antigen(HBcrAg)correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients", J Hepatol, 70, pp.615~625 (2019)
8. Tseng TC, "Low Hepatitis B core-related antigen levels correlate higher spontaneous seroclearance of hepatitis B surface antigen in chronic hepatitis B patients with high hepatitis B surface antigen levels", Gastroenterology, 164, pp.669~679 (2023)
9. Tseng TC, "Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load", Aliment Pharmacol Ther, 53, pp.908~918 (2021)
10. Tseng TC, "High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load", Gastroenterology, 157, pp.1518~1529 (2019)
11. Tsai YN, "Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation", Clin Mol Hepatol, 30, pp.98~108 (2024)
12. Inoue T, "Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation", J Hepatol, 75, pp.302~310 (2021)
13. Cao J, "Off-treatment hepatitis B virus(HBV)DNA levels and the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B : A prospective stop study", J Infect Dis, 215, pp.581~589 (2017)
14. Sonneveld MJ, "HBV DNA and HBsAg levels at 24 weeks off-treatment predict clinical relapse and HBsAg loss in HBeAg-negative patients who discontinued antiviral therapy", Gastroenterology, 166, pp.168~177 (2024)

관련 논문AI추천